HealthcareFirms.com » Cancer

Cannabis Science, Inc.

admin — Wed, 03 Mar 2010 00:29:30 +0000

Cannabis Science, Inc. is at the forefront of medical marijuana research and development. The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce, and commercialize phytocannabinoid-based pharmaceutical products. The Company is dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.

Pro-Pharmaceuticals Inc.

admin — Wed, 03 Mar 2010 00:29:30 +0000

Pro-Pharmaceuticals is engaged in the discovery, development and commercialization of carbohydrate therapeutics that target galectin receptors for advanced treatment of cancer and fibrosis. Initially, the product pipeline is focused on increasing the efficacy and decreasing the toxicity of chemotherapy drugs.

Marshall Edwards Inc.

admin — Tue, 02 Mar 2010 18:40:16 +0000

Marshall Edwards, Inc. is a pharmaceutical company dedicated to the field of cancer therapy. It is developing a range of anti-cancer therapies that represents the next generation of oncology drugs – multiple signal transduction regulators (‘MSTR’) that reach to the heart of the cancer process. The source of this new range of drugs is a family of chemicals, discovered by pharmaceutical company Novogen, that act against the fundamentals of the cancer process. Using this single technology platform, MEI is developing a number of drugs with novel actions against a range of different cancer types.

Telik Inc.

admin — Tue, 02 Mar 2010 18:40:16 +0000

Telik, Inc. of Palo Alto, CA, is a clinical stage drug development company focused on discovering and developing small molecule drugs to treat cancer. The company’s most advanced drug candidates in clinical development are TELINTRA, a modified glutathione analog for the treatment of cytopenias due to myelodysplastic syndrome or chemotherapy, and TELCYTA, a tumor-activated prodrug for the treatment of advanced non-small cell lung cancer and ovarian cancer. Telik’s product candidates were discovered using its proprietary drug discovery technology, TRAP, which enables the rapid and efficient discovery of small molecule drug candidates.

Geron Corporation

admin — Tue, 02 Mar 2010 18:40:16 +0000

Geron is developing first-in-class biopharmaceuticals for the treatment of cancer and chronic degenerative diseases, including spinal cord injury, heart failure and diabetes. The company is advancing an anti-cancer drug and a cancer vaccine that target the enzyme telomerase through multiple clinical trials in different cancers.

Lescarden Inc.

admin — Tue, 02 Mar 2010 18:40:16 +0000

Lescarden Incorporated is a biotechnology company dedicated to the research and development of proprietary biologic materials with a focus on wound healing, clinical skin care, osteoarthritis, autoimmune and cancer applications. Lescarden

Pharmacyclics Inc.

admin — Tue, 02 Mar 2010 18:40:16 +0000

Pharmacyclics is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative small-molecule drugs for the treatment of immune mediated disease and cancer. The purpose of the company is to create a profitable business by generating income from products it develops, licenses and commercializes, either with one or several potential partners or alone as may best forward the economic interest of its stakeholders. The Company endeavors to create novel, patentable, differentiated products that have the potential to significantly improve the standard of care in the markets it serves. Presently, Pharmacyclics has four product candidates in clinical development and two product candidates in pre-clinical development. It is Pharmacyclics’ business strategy to establish collaborations with large pharmaceutical and biotechnology companies for the purpose of generating present and future income in exchange for adding to their product pipelines. Pharmacyclics strives to generate collaborations that allow it to retain valuable territorial rights and simultaneously fast forward the clinical development and commercialization of its products. The Company is headquartered in Sunnyvale, California.

SuperGen Inc.

admin — Tue, 02 Mar 2010 18:40:16 +0000

SuperGen is a pharmaceutical company dedicated to the discovery and development of novel cancer therapeutics in epigenetic and cell signaling modulation. The Company develops products through biochemical and clinical proof of concept to partner for further development and commercialization.

Vertex Pharmaceuticals

admin — Tue, 02 Mar 2010 18:40:16 +0000

Vertex Pharmaceuticals Incorporated is a global biotechnology company committed to the discovery and development of breakthrough small molecule drugs for serious diseases. The Company’s strategy is to commercialize its products both independently and in collaboration with major pharmaceutical companies. Vertex’s product pipeline is focused on viral diseases, cystic fibrosis, inflammation, autoimmune diseases, cancer, and pain.

Allos Therapeutics, Inc.

admin — Fri, 26 Feb 2010 18:31:21 +0000

Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. Allos is currently focused on the development and commercialization of FOLOTYNTM (pralatrexate injection), a folate analogue metabolic inhibitor. FOLOTYN is the first and only drug approved in the U.S. for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma. Allos is also exploring the potential of FOLOTYN in other indications.

Ardea Biosciences, Inc.

admin — Fri, 26 Feb 2010 18:31:21 +0000

Ardea Biosciences, Inc., of San Diego, California, is a biotechnology company focused on the development of small-molecule therapeutics for the treatment of gout, cancer and human immunodeficiency virus. RDEA594, its lead product candidate in development for the treatment of hyperuricemia and gout, is a selective URAT1 transporter inhibitor in Phase 2 clinical development. Its next-generation URAT1 inhibitor, RDEA684, is currently in preclinical development. RDEA119, a potent and specific inhibitor of mitogen-activated ERK kinase (MEK), is being developed under a global license agreement with Bayer HealthCare AG.

Arena Pharmaceuticals, Inc.

admin — Fri, 26 Feb 2010 18:31:21 +0000

Arena is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs that target G protein-coupled receptors, an important class of validated drug targets, in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases. Arena’s most advanced drug candidate, lorcaserin, is intended for weight management, including weight loss and maintenance of weight loss, and has completed a pivotal Phase 3 clinical trial program. Arena recently submitted an NDA for lorcaserin to the FDA.

ArQule Inc.

admin — Fri, 26 Feb 2010 18:31:21 +0000

ArQule is a biotechnology company engaged in the research and development of next-generation, small-molecule cancer therapeutics. The Company’s targeted, broad-spectrum products and research programs are focused on key biological processes that are central to human cancers. ArQule’s lead product, in Phase 2 clinical development, is ARQ 197, an inhibitor of the c-Met receptor tyrosine kinase. The Company is also conducting Phase 1 clinical testing with ARQ 621, designed to inhibit the Eg5 kinesin motor protein. The Company’s pre-clinical pipeline includes programs directed toward inhibition of the B-RAF kinase and inhibition of fibroblast growth factor receptor. ArQule’s current discovery efforts, which are based on the ArQule Kinase Inhibitor Platform (AKIP(TM)), are focused on the identification of novel kinase inhibitors that are potent, selective and do not compete with ATP (adenosine triphosphate) for binding to the kinase.

OSI Pharmaceuticals Inc.

admin — Sun, 21 Feb 2010 18:37:26 +0000

OSI Pharmaceuticals is a profitable biotechnology company that discovers, develops and commercializes innovative molecular targeted therapies addressing major unmet medical needs in oncology, diabetes and obesity. OSI’s strategic focus is in the area of personalized medicine. It is building upon the knowledge and insights from its flagship product, Tarceva, in order to establish a leadership role in turning the promise of personalized medicine into practice in oncology and in pioneering the adoption of personalized medicine approaches in diabetes and obesity.

PDL BioPharma, Inc.

admin — Sun, 21 Feb 2010 18:37:26 +0000

PDL pioneered the humanization of monoclonal antibodies and, by doing so, enabled the discovery of a new generation of targeted treatments for cancer and immunologic diseases. PDL is focused on maximizing the value of its antibody humanization patents and related assets. The Company receives royalties on sales of a number of humanized antibody products.

Peregrine Pharmaceuticals Inc.

admin — Sun, 21 Feb 2010 18:37:26 +0000

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative product candidates in clinical trials for the treatment of cancer and serious virus infections. The company is pursuing three separate clinical programs in cancer and HCV infection with its lead product candidates bavituximab and Cotara(R). Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc., which provides development and bio-manufacturing services for both Peregrine and outside customers.

Poniard Pharmaceuticals, Inc.

admin — Sun, 21 Feb 2010 18:37:26 +0000

Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative oncology products to impact the lives of people with cancer. Poinard is currently focusing on development efforts of picoplatin, a new generation platinum chemotherapy agent with the potential to become a platform product addressing multiple indications, combinations and formulations.

Progenics Pharmaceuticals Inc.

admin — Sun, 21 Feb 2010 18:37:26 +0000

Progenics Pharmaceuticals, Inc. is a biopharmaceutical company focusing on the development and commercialization of innovative therapeutic products to treat the unmet medical needs of patients with debilitating conditions and life-threatening diseases. Principal programs are directed toward supportive care, virology and oncology. Progenics is developing RELISTOR(R) (methylnaltrexone bromide) for the treatment of opioid-induced side effects. RELISTOR is currently approved in over 30 countries, including the U.S., E.U. member countries, Canada, Australia and Brazil; marketing applications are pending elsewhere throughout the world.

Lexicon Pharmaceuticals, Inc.